#Germany #ADLM 2026 #SphingoTec #Deborah Bergmann #Hennigsdorf

SphingoTec CEO Deborah Bergmann to Attend ADLM 2026

SphingoTec GmbH has officially announced the participation of its Chief Executive Officer, Deborah Bergmann, in the upcoming ADLM 2026 Annual Meeting, scheduled from July 26 to 30, 2026. This significant event is expected to be crucial for professionals in the diagnostics field, providing an excellent platform for networking and discussing the latest advancements in medical science.

A Platform for Innovation

During the event, SphingoTec aims to engage with both existing and potential partners to discuss its ongoing collaborations and to explore new opportunities in the realm of critical care diagnostics. Bergmann expressed a strong commitment to integrating biomarker innovation into tangible and clinically meaningful solutions for patients in critical conditions. "ADLM provides an important platform to connect with partners across the diagnostics ecosystem," she said, emphasizing the alignment of these conversations with the company's ambitions for growth and innovation.

Pioneering Biomarker Solutions

SphingoTec, headquartered in Hennigsdorf near Berlin, Germany, is known for its cutting-edge biomarker technologies focused on diagnosing, predicting, and monitoring acute medical conditions. The company's offerings are tailored towards making critical care diagnostics more accessible and effective. Among the innovations in its portfolio is Proenkephalin A 119-159, commonly referred to as penKid, which serves as a biomarker for assessing kidney function in critically ill patients. Additionally, SphingoTec’s bioactive Adrenomedullin 1-52 (bio-ADM) is crucial for evaluating endothelial function in scenarios such as sepsis.

Working Toward the Future of Diagnostics

The commitment of SphingoTec to advancing healthcare solutions is evident through its strategic approach at events like ADLM. By fostering connections with key figures in the diagnostics field, the company is working toward enhancing its clinical and commercial reach, ensuring that vital biomarker innovations transition to commercial stages swiftly.

These interactions at ADLM 2026 will not only bolster SphingoTec's partnerships but also support the broader objective of revolutionizing critical care diagnostics. The emphasis on collaboration underlines the importance of working together within the medical community to improve patient outcomes through enhanced diagnostic capabilities.

With healthcare becoming increasingly reliant on precise and timely diagnostics, the presence of innovations like those from SphingoTec becomes more crucial. The participation of its CEO at such a high-level conference signifies the company’s dedication to remaining at the forefront of the field, ensuring that healthcare professionals have access to the best tools and technologies available.

To learn more about SphingoTec and its pioneering work in biomarker solutions, visit www.sphingotec.com.